Literature DB >> 3124926

Management of retinal vein occlusion.

P Merry, J F Acheson, R A Asherson, G R Hughes.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3124926      PMCID： PMC2544798          DOI： 10.1136/bmj.296.6617.294

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN： 0267-0623


× No keyword cloud information.
  7 in total

1.  Antibodies to cardiolipin in young survivors of myocardial infarction: an association with recurrent cardiovascular events.

Authors:  A Hamsten; R Norberg; M Björkholm; U de Faire; G Holm
Journal:  Lancet       Date:  1986-01-18       Impact factor: 79.321

2.  The lupus anticoagulant in 14 male patients.

Authors:  C C Waddell; J A Brown
Journal:  JAMA       Date:  1982-11-19       Impact factor: 56.272

3.  Thrombosis in systemic lupus erythematosus: striking association with the presence of circulating lupus anticoagulant.

Authors:  M L Boey; C B Colaco; A E Gharavi; K B Elkon; S Loizou; G R Hughes
Journal:  Br Med J (Clin Res Ed)       Date:  1983-10-08

4.  Recurrent ischemic attacks in two young adults with lupus anticoagulant.

Authors:  G Landi; M V Calloni; M Grazia Sabbadini; P Mannuccio Mannucci; L Candelise
Journal:  Stroke       Date:  1983 May-Jun       Impact factor: 7.914

5.  Anticardiolipin antibodies: isotype distribution and phospholipid specificity.

Authors:  A E Gharavi; E N Harris; R A Asherson; G R Hughes
Journal:  Ann Rheum Dis       Date:  1987-01       Impact factor: 19.103

6.  Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus.

Authors:  E N Harris; A E Gharavi; M L Boey; B M Patel; C G Mackworth-Young; S Loizou; G R Hughes
Journal:  Lancet       Date:  1983-11-26       Impact factor: 79.321

7.  Severe retinal vaso-occlusive disease in systemic lupus erythematous.

Authors:  D A Jabs; S L Fine; M C Hochberg; S A Newman; G G Heiner; M B Stevens
Journal:  Arch Ophthalmol       Date:  1986-04
  7 in total
  6 in total

1.  Occlusive ocular vascular disease and antiphospholipid antibodies.

Authors:  C Tolosa-Vilella; J Ordi-Ros; R Jordana-Comajuncosa; A Selva-O'Callaghan; M Vilardell-Tarres
Journal:  Ann Rheum Dis       Date:  1990-03       Impact factor: 19.103

Review 2.  Antiphospholipid syndrome: linking many specialties.

Authors:  G R Hughes; R A Asherson; M A Khamashta
Journal:  Ann Rheum Dis       Date:  1989-05       Impact factor: 19.103

Review 3.  Investigation of visual loss: neuro-ophthalmology from a neurologist's perspective.

Authors:  C J Lueck
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-03       Impact factor: 10.154

4.  Anticardiolipin antibodies and occlusive vascular disease of the eye: prospective study.

Authors:  C D Kalogeropoulos; P Spyrou; M I Stefaniotou; E E Tsironi; A A Drosos; K G Psilas
Journal:  Doc Ophthalmol       Date:  1998       Impact factor: 2.379

5.  Antiphospholipid antibodies: a risk factor for occlusive ocular vascular disease in systemic lupus erythematosus and the 'primary' antiphospholipid syndrome.

Authors:  R A Asherson; P Merry; J F Acheson; E N Harris; G R Hughes
Journal:  Ann Rheum Dis       Date:  1989-05       Impact factor: 19.103

Review 6.  [Antiphospholipid syndrome and retinal vein occlusion. Meta-analysis of Published Studies].

Authors:  M Rehak; M Müller; M Scholz; J Wiercinska; D Niederwieser; P Wiedemann
Journal:  Ophthalmologe       Date:  2009-05       Impact factor: 1.059
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.